# Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

DOI: 10.1002/(sici)1521-4141(199806)28:063.0.co;2-8
European Journal of Immunology, 1998, 28, 2045-54.

| # | Paper | IF | Citations |
|---|---|---|---|
| 717 | CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. **1998**, 17, 6230-40 | | 509 |
| 716 | Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. *European Journal of Immunology*, **1998**, 28, 2045-54 | 6.1 | 698 |
| 715 | Bacterial DNA as immune cell activator. **1998**, 6, 496-500 | | 108 |
| 714 | Type I interferon-mediated stimulation of T cells by CpG DNA. **1998**, 188, 2335-42 | | 322 |
| 713 | Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. **1999**, 11, 1111-8 | | 94 |
| 712 | CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. **1999**, 96, 9305-10 | | 525 |
| 711 | DNA vaccination: transfection and activation of dendritic cells as key events for immunity. **1999**, 189, 169-78 | | 323 |
| 710 | Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. **1999**, 10, 223-34 | | 180 |
| 709 | Bacterial CpG DNA activates immune cells to signal infectious danger. **1999**, 73, 329-68 | | 241 |
| 708 | The role of dendritic cells in the induction and regulation of immunity to microbial infection. **1999**, 11, 392-9 | | 243 |
| 707 | CpG-DNA upregulates the major acute-phase proteins SAA and SAP. **1999**, 1, 61-7 | | 13 |
| 706 | DNA activates human immune cells through a CpG sequence-dependent manner. **1999**, 97, 699-705 | | 118 |
| 705 | Simple chemicals can induce maturation and apoptosis of dendritic cells. **1999**, 98, 481-90 | | 66 |
| 704 | Gene therapy of viral hepatitis and hepatocellular carcinoma. **1999**, 6, 17-34 | | 23 |
| 703 | Advances in vaccine adjuvants. **1999**, 17, 1075-81 | | 418 |
| 702 | Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. **1999**, 168, 217-39 | | 46 |
| 701 | Stimulation of naïve and memory T cells by cytokines. **1999**, 170, 39-47 | | 94 |

| | | | |
|---|---|---|---|
| 700 | Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. **1999**, 6, 1779-84 | | 108 |
| 699 | LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. **1999**, 6, 1867-75 | | 189 |
| 698 | Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. **1999**, 6, 1972-81 | | 70 |
| 697 | Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. **1999**, 197, 62-72 | | 96 |
| 696 | Adjuvant effect of a 14-member macrolide antibiotic on DNA vaccine. **1999**, 197, 145-50 | | 4 |
| 695 | Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. **1999**, 198, 69-75 | | 75 |
| 694 | Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. **1999**, 18, 6973-82 | | 93 |
| 693 | Cytokine regulation of CD40 expression in fetal human astrocyte cultures. **1999**, 101, 7-14 | | 32 |
| 692 | Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. **1999**, 1489, 107-16 | | 113 |
| 691 | Nucleic acid immunization: concepts and techniques associated with third generation vaccines. **1999**, 229, 1-22 | | 76 |
| 690 | CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. *European Journal of Immunology*, **1999**, 29, 1209-18 | 6.1 | 138 |
| 689 | Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. *European Journal of Immunology*, **1999**, 29, 2344-53 | 6.1 | 157 |
| 688 | Guanosine-rich oligodeoxynucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells. *European Journal of Immunology*, **1999**, 29, 3496-506 | 6.1 | 30 |
| 687 | Direct Immunologic activities of CpG DNA and implications for gene therapy. **1999**, 1, 56-63 | | 9 |
| 686 | The host response to Leishmania infection. **2000**, 74, 275-317 | | 128 |
| 685 | In vivo transfer of bacterial marker genes results in differing levels of gene expression and tumor progression in immunocompetent and immunodeficient mice. **1999**, 10, 2373-9 | | 9 |
| 684 | Immune recognition of foreign DNA: a cure for bioterrorism?. **1999**, 11, 123-9 | | 107 |
| 683 | Modulation of host immune responses by protozoal DNA. **1999**, 72, 87-94 | | 13 |

| | | | |
|---|---|---|---|
| 682 | Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. **1999**, 17, 3065-71 | | 124 |
| 681 | Immunostimulatory DNA and applications to allergic disease. **1999**, 104, 902-10 | | 55 |
| 680 | Dendritic cell activation induced by various stimuli, e.g. exposure to microorganisms, their products, cytokines, and simple chemicals as well as adhesion to extracellular matrix. **1998**, 20, 1-13 | | 34 |
| 679 | Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. **2000**, 165, 1182-90 | | 112 |
| 678 | Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. **2000**, 165, 3631-9 | | 60 |
| 677 | Preferential stimulation of human lymphocytes by oligodeoxynucleotides that copy DNA CpG motifs present in virulent genes of group A streptococci. *European Journal of Immunology*, **2000**, 30, 993-1001 | 6.1 | 13 |
| 676 | The major role of macrophages and their product tumor necrosis factor alpha in the induction of arthritis triggered by bacterial DNA containing CpG motifs. **2000**, 43, 2283-9 | | 53 |
| 675 | The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. *European Journal of Immunology*, **2000**, 30, 2211-5 | 6.1 | 249 |
| 674 | Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. *European Journal of Immunology*, **2000**, 30, 1841-50 | 6.1 | 76 |
| 673 | Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. *European Journal of Immunology*, **2000**, 30, 1939-47 | 6.1 | 142 |
| 672 | Response of human monocyte-derived dendritic cells to immunostimulatory DNA. *European Journal of Immunology*, **2000**, 30, 2824-31 | 6.1 | 31 |
| 671 | Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. *European Journal of Immunology*, **2000**, 30, 3291-8 | 6.1 | 76 |
| 670 | Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. *European Journal of Immunology*, **2000**, 30, 3591-7 | 6.1 | 154 |
| 669 | Interleukin-10 does not affect phagocytosis of particulate antigen by bone marrow-derived dendritic cells but does impair antigen presentation. **2000**, 99, 523-31 | | 52 |
| 668 | Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. **2000**, 101, 46-52 | | 40 |
| 667 | Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method. **2000**, 99, 179-86 | | 35 |
| 666 | Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming and differentiation of CD8+ T cells. **2000**, 99, 1-7 | | 24 |
| 665 | Mycobacterium tuberculosis-activated dendritic cells induce protective immunity in mice. **2000**, 99, 473-80 | | 87 |

| | | |
|---|---|---|
| 664 | CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. **2000**, 99, 170-8 | 75 |
| 663 | The effects of DNA containing CpG motif on dendritic cells. **2000**, 99, 361-6 | 53 |
| 662 | Dendritic cells: immunological sentinels with a central role in health and disease. **2000**, 78, 91-102 | 100 |
| 661 | B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. **2000**, 176, 154-70 | 312 |
| 660 | The role of dendritic cells in the innate immune system. **2000**, 2, 257-72 | 86 |
| 659 | Accessible 5Pend of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. **2000**, 10, 2585-8 | 70 |
| 658 | Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. **2000**, 21, 521-6 | 110 |
| 657 | Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. **2000**, 7, 1137-47 | 32 |
| 656 | A Toll-like receptor recognizes bacterial DNA. **2000**, 408, 740-5 | 5206 |
| 655 | Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. **2000**, 10, 1139-42 | 204 |
| 654 | Molecular events of bacterial-induced maturation of dendritic cells. **2000**, 20, 161-6 | 55 |
| 653 | T cell immunity in neonates. **2000**, 22, 177-90 | 127 |
| 652 | Mucosal adjuvanticity of immunostimulatory DNA sequences. **2000**, 22, 133-46 | 7 |
| 651 | The role of CpG in DNA vaccines. **2000**, 22, 125-32 | 34 |
| 650 | Rescue of B cells from apoptosis by immune stimulatory CpG DNA. **2000**, 22, 55-61 | 13 |
| 649 | The response of human B lymphocytes to oligodeoxynucleotides. **2000**, 22, 63-75 | 8 |
| 648 | Mechanisms of immune stimulation by bacterial DNA. **2000**, 22, 21-33 | 25 |
| 647 | Immunostimulatory DNA sequences and cancer therapy. **2000**, 22, 107-16 | 11 |

| | | |
|---|---|---|
| 646 | The role of immunostimulatory CpG-DNA in septic shock. **2000**, 22, 167-71 | 6 |
| 645 | Immunostimulatory DNA sequences help to eradicate intracellular pathogens. **2000**, 22, 147-52 | 5 |
| 644 | Pre-priming: a novel approach to DNA-based vaccination and immunomodulation. **2000**, 22, 85-96 | 7 |
| 643 | Activation of skin dendritic cells by immunostimulatory DNA. **2000**, 22, 45-54 | 2 |
| 642 | Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. **2000**, 22, 77-84 | 23 |
| 641 | Introduction to immunostimulatory DNA sequences. **2000**, 22, 1-9 | 20 |
| 640 | Immunology of DNA vaccines: CpG motifs and antigen presentation. **2000**, 49, 199-205 | 21 |
| 639 | Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. **2000**, 95, 999-1006 | 183 |
| 638 | Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. **2000**, 164, 1617-24 | 512 |
| 637 | CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. **2000**, 68, 1450-6 | 75 |
| 636 | APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. **2000**, 165, 6244-51 | 72 |
| 635 | CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. **2000**, 165, 6889-95 | 110 |
| 634 | Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. **2000**, 164, 4507-12 | 425 |
| 633 | CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. **2000**, 165, 5906-12 | 108 |
| 632 | CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. **2000**, 164, 5683-8 | 142 |
| 631 | Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. **2000**, 165, 539-47 | 121 |
| 630 | CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. **2000**, 164, 973-85 | 55 |
| 629 | Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. **2000**, 11, 1731-41 | 44 |

| | | |
|---|---|---|
| 628 | Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. **2000**, 165, 6278-86 | 148 |
| 627 | The role of bacterial DNA in septic arthritis. **2000**, 6, 29-33 | 7 |
| 626 | Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. **2000**, 22, 176-82 | 59 |
| 625 | Synthetic oligodeoxynucleotides inhibit IgE induction in human lymphocytes. **2000**, 162, 232-9 | 26 |
| 624 | Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. **2000**, 1, 255-62 | 185 |
| 623 | Basic mechanisms of DNA-raised antibody responses to intramuscular and gene gun immunizations. **2000**, 19, 157-65 | 42 |
| 622 | CpG motifs induce Langerhans cell migration in vivo. **2000**, 12, 737-45 | 63 |
| 621 | Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. **2000**, 165, 4537-43 | 113 |
| 620 | Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. **2000**, 68, 4923-9 | 33 |
| 619 | CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. **2000**, 165, 1228-35 | 118 |
| 618 | Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. **2000**, 74, 9617-28 | 202 |
| 617 | CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. **2000**, 164, 2372-8 | 119 |
| 616 | CpG DNA as a Th1 trigger. **2000**, 121, 87-97 | 90 |
| 615 | Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. **2000**, 96, 198-204 | 58 |
| 614 | In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. **2000**, 19, 23-32 | 75 |
| 613 | CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. **2000**, 19, 234-42 | 38 |
| 612 | Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. **2000**, 19, 413-22 | 128 |
| 611 | CpG DNA is an effective oral adjuvant to protein antigens in mice. **2000**, 19, 950-7 | 88 |

| | | |
|---|---|---|
| 610 | Immune effects and mechanisms of action of CpG motifs. **2000**, 19, 618-22 | 127 |
| 609 | Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant. **2000**, 95, S19-29 | 18 |
| 608 | Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. **2000**, 164, 5575-82 | 148 |
| 607 | Requirements for effective inhibition of immunostimulatory CpG motifs by neutralizing motifs. **2000**, 10, 381-9 | 17 |
| 606 | Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. **2000**, 191, 423-34 | 1209 |
| 605 | Mechanism and function of a newly identified CpG DNA motif in human primary B cells. **2000**, 164, 944-53 | 530 |
| 604 | [Antitumor immunology in the year 2000 and the new immunosuppressive therapy]. **2000**, 114, 579-83 | 0 |
| 603 | Regulation of immunologic homeostasis in peripheral tissues by dendritic cells: the respiratory tract as a paradigm. **2000**, 105, 421-9 | 91 |
| 602 | CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. **2000**, 1, 57-61 | 36 |
| 601 | T-cell activation and polarization by dendritic cells. **2001**, 21-cp1 | |
| 600 | Toll-like receptors and innate immunity. **2001**, 78, 1-56 | 249 |
| 599 | Regulation of interleukin-12 production in antigen-presenting cells. **2001**, 79, 55-92 | 153 |
| 598 | Synovial cytokine mRNA expression during arthritis triggered by CpG motifs of bacterial DNA. **2001**, 3, 48-53 | 14 |
| 597 | Immunostimulatory CpG oligodeoxynucleotides stimulate expression of IL-1beta and interferon-like cytokines in rainbow trout macrophages via a chloroquine-sensitive mechanism. **2001**, 11, 673-82 | 74 |
| 596 | CpG-oligonucleotides in vaccination: signaling and mechanisms of action. **2001**, 204, 667-76 | 19 |
| 595 | Dendritic cells as vectors for vaccination against infectious diseases. **2001**, 291, 323-9 | 19 |
| 594 | The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. **2001**, 19, 2657-60 | 41 |
| 593 | Adjuvantation of epidermal powder immunization. **2001**, 19, 2908-17 | 54 |

| | | |
|---|---|---|
| 592 | Protective CTL response is induced in the absence of CD4+ T cells and IFN-gamma by gene gun DNA vaccination with a minigene encoding a CTL epitope of Listeria monocytogenes. **2001**, 19, 4297-306 | 22 |
| 591 | Features of the antibody response attributable to plasmid backbone adjuvanticity after DNA immunization. **2001**, 19, 4549-56 | 8 |
| 590 | CpG oligodeoxynucleotides and plasmid DNA stimulate Atlantic salmon (Salmo salar L.) leucocytes to produce supernatants with antiviral activity. **2001**, 25, 313-21 | 101 |
| 589 | Peptide vaccines against hepatitis B virus: from animal model to human studies. **2001**, 38, 457-65 | 39 |
| 588 | Role of dendritic cell-derived cytokines in immune regulation. **2001**, 7, 977-92 | 26 |
| 587 | CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. **2001**, 11, 333-40 | 180 |
| 586 | Dendritic Cells in Cancer Immunotherapy. **2001**, 21, 13 | 25 |
| 585 | The Potential of CpG Oligodeoxynucleotides as Mucosal Adjuvants. **2001**, 21, 18 | 1 |
| 584 | Allergen uptake and presentation by dendritic cells. **2001**, 1, 51-59 | 52 |
| 583 | Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. **2001**, 98, 1512-23 | 188 |
| 582 | The dendritic cell in allergic airway diseases: a new player to the game. **2001**, 31, 206-18 | 44 |
| 581 | The role of surface ig binding in the activation of human B cells by phosphorothioate oligodeoxynucleotides. **2001**, 54, 551-63 | 9 |
| 580 | The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. **2001**, 103, 226-34 | 65 |
| 579 | Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. **2001**, 9, 807-13 | 64 |
| 578 | Recent developments in adjuvants for vaccines against infectious diseases. **2001**, 18, 69-85 | 269 |
| 577 | CpG oligonucleotide modulation of allergic inflammation. **2001**, 56, 365-76 | 37 |
| 576 | DNA-based immunotherapeutics for the treatment of allergic disease. **2001**, 179, 102-18 | 86 |
| 575 | Active immunization against cancer with dendritic cells: the near future. **2001**, 94, 459-73 | 269 |

| | | | |
|---|---|---|---|
| 574 | CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes. *European Journal of Immunology*, **2001**, 31, 301-10 | 6.1 | 44 |
| 573 | Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. *European Journal of Immunology*, **2001**, 31, 3525-34 | 6.1 | 64 |
| 572 | Annotated References by Year. **2001**, 651-770 | | |
| 571 | DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. **2001**, 214, 60-71 | | 36 |
| 570 | Type I IFN modulates the immune response induced by DNA vaccination to pseudorabies virus glycoprotein C. **2001**, 286, 197-205 | | 26 |
| 569 | Dendritic cell lineage, plasticity and cross-regulation. **2001**, 2, 585-9 | | 502 |
| 568 | Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. **2001**, 8, 128-38 | | 23 |
| 567 | Erratum A Toll-like receptor recognizes bacterial DNA. **2001**, 409, 646-646 | | 9 |
| 566 | Tailoring cancer vaccines to the elderly: the importance of suitable mouse models. **2001**, 122, 1087-105 | | 14 |
| 565 | Costimulation via lymphocyte function-associated antigen 1 in the absence of CD28 ligation promotes anergy of naive CD4+ T cells. **2001**, 98, 241-246 | | 40 |
| 564 | Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. **2001**, 166, 5000-7 | | 263 |
| 563 | Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. **2001**, 166, 5236-44 | | 140 |
| 562 | Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. **2001**, 167, 66-74 | | 110 |
| 561 | Genomic DNA released by dying cells induces the maturation of APCs. **2001**, 167, 2602-7 | | 206 |
| 560 | A novel function of phosphorothioate oligodeoxynucleotides as chemoattractants for primary macrophages. **2001**, 167, 2847-54 | | 39 |
| 559 | Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. **2001**, 167, 3765-72 | | 54 |
| 558 | Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. **2001**, 167, 4878-86 | | 205 |
| 557 | NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. **2001**, 167, 5247-53 | | 178 |

| | | |
|---|---|---|
| 556 | Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. **2001**, 3, 673-82 | 86 |
| 555 | Dendritic cells: immunological features and utilisation for tumour immunotherapy. **2001**, 5, 491-506 | 4 |
| 554 | Novel activators of dendritic cells as fundamental tools in immunotherapy. **2001**, 11, 1411-1421 | |
| 553 | Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. **2001** , 166, 2372-7 | 447 |
| 552 | Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. **2001**, 167, 1584-91 | 97 |
| 551 | Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. **2001**, 167, 3316-23 | 155 |
| 550 | Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. **2001**, 166, 2291-5 | 239 |
| 549 | IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. **2001**, 167, 1179-87 | 343 |
| 548 | Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria. **2001**, 69, 4351-7 | 62 |
| 547 | Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. **2001**, 69, 6156-64 | 67 |
| 546 | Defined synthetic vaccines. **2001**, 382, 581-95 | 23 |
| 545 | Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. **2001**, 166, 3451-7 | 200 |
| 544 | Type 1/Type 2 immunity in infectious diseases. **2001**, 32, 76-102 | 771 |
| 543 | Novel adjuvant systems. **2001**, 1, 263-71 | 46 |
| 542 | From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. **2001**, 11, 181-8 | 47 |
| 541 | Cytokines and Colony Stimulating Factors. **2002**, | |
| 540 | DNA containing CpG motifs induces angiogenesis. **2002**, 99, 8944-9 | 82 |
| 539 | Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. **2002**, 168, 171-8 | 700 |

| | | |
|---|---|---|
| 538 | Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. **2002**, 169, 350-8 | 347 |
| 537 | CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. **2002**, 168, 1212-8 | 127 |
| 536 | Oral DNA vaccination in utero induces mucosal immunity and immune memory in the neonate. **2002**, 168, 1877-85 | 42 |
| 535 | Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. **2002**, 168, 4951-9 | 90 |
| 534 | Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. **2002**, 168, 4711-20 | 179 |
| 533 | Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. **2002**, 168, 5233-9 | 545 |
| 532 | Codelivery of NF-kappaB decoy-related oligodeoxynucleotide improves LPD-mediated systemic gene transfer. **2002**, 6, 804-12 | 25 |
| 531 | Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3POH kinase pathway. **2002**, 168, 5-8 | 87 |
| 530 | B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12. **2002**, 169, 787-94 | 49 |
| 529 | Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. **2002**, 169, 3892-9 | 163 |
| 528 | Immunology of vaccination. **2002**, 62, 15-28 | 35 |
| 527 | Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. **2002**, 76, 2676-82 | 81 |
| 526 | CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. **2002**, 5, 731-8 | 184 |
| 525 | Toll-like receptor 9, CpG DNA and innate immunity. **2002**, 2, 545-56 | 116 |
| 524 | Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. **2002**, 169, 2781-7 | 131 |
| 523 | CpG motifs as possible adjuvants for the treatment of allergic diseases. **2002**, 129, 198-203 | 26 |
| 522 | Stimulatory effect of CpG sequences on humoral response in chickens. **2002**, 81, 1317-21 | 46 |
| 521 | The role of dendritic cells at the early stages of Leishmania infection. **2000**, 479, 163-73 | 22 |

| | | |
|---|---|---|
| 520 | The Biology and Pathology of Innate Immunity Mechanisms. **2002**, | 2 |
| 519 | Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. **2002**, 16, 1749-54 | 28 |
| 518 | Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. **2002**, 76, 6568-76 | 48 |
| 517 | In vitro maturation of dendritic cells from blood progenitors. **2003**, 215, 417-26 | |
| 516 | Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. **2002**, 100, 1133-40 | 83 |
| 515 | Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. **2002**, 100, 2537-45 | 48 |
| 514 | Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. **2002**, 100, 4169-76 | 67 |
| 513 | The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. **2002**, 227, 227-37 | 38 |
| 512 | Adjuvants and malaria vaccine development. **2002**, 80, 343-65 | 8 |
| 511 | Evaluation of dendritic cell immunogenicity after activation and chemical fixation: a mixed lymphocyte reaction model. **2002**, 25, 152-61 | 1 |
| 510 | Cytokine gene transfer into dendritic cells for cancer treatment. **2002**, 2, 79-89 | 20 |
| 509 | Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. **2002** , 169, 1326-33 | 80 |
| 508 | CpG oligodeoxynucleotides as vaccine adjuvants in primates. **2002**, 168, 1659-63 | 169 |
| 507 | CpG motifs in bacterial DNA and their immune effects. **2002**, 20, 709-60 | 2122 |
| 506 | Analysis of the gene expression profiles of immature versus mature bone marrow-derived dendritic cells using DNA arrays. **2002**, 290, 66-72 | 52 |
| 505 | Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. **2002**, 109, 455-62 | 129 |
| 504 | Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. **2002**, 110, 413-20 | 47 |
| 503 | Growth factors, cytokines and dendritic cell development. **2002**, 8, 405-18 | 11 |

| | | | |
|---|---|---|---|
| 502 | CpG DNA in the prevention and treatment of infections. **2002**, 16, 419-31 | | 33 |
| 501 | Overcoming the inflammatory toxicity of cationic gene vectors. **2002**, 10, 153-60 | | 23 |
| 500 | Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. **2002**, 94, 805-18 | | 335 |
| 499 | Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. **2002**, 5, 62-9 | | 160 |
| 498 | Plasmacytoid dendritic cells: the key to CpG. **2002**, 63, 1111-9 | | 122 |
| 497 | Mechanisms of stimulation of the immune response by aluminum adjuvants. **2002**, 20 Suppl 3, S34-9 | | 231 |
| 496 | Activation of antigen-presenting cells by immunostimulatory plant DNA: a natural resource for potential adjuvant. **2002**, 20, 2764-71 | | 12 |
| 495 | CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. **2002**, 20, 3014-22 | | 56 |
| 494 | Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. **2002**, 20, 3389-98 | | 28 |
| 493 | Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. **2002**, 20, 3342-54 | | 64 |
| 492 | CpG-oligodinucleotides as an effective adjuvant in pigs for intramuscular immunizations. **2002**, 86, 31-41 | | 39 |
| 491 | Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. **2002**, 168, 4531-7 | | 1574 |
| 490 | . **2002**, | | 5 |
| 489 | Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. **2002**, 76, 11397-404 | | 49 |
| 488 | Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. **2002**, 29, 93-97 | | 15 |
| 487 | Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice. **2002**, 101, 3-12 | | 17 |
| 486 | Toll-like receptor 4 is not required for the full maturation of dendritic cells or for the degradation of Gram-negative bacteria. *European Journal of Immunology*, **2002**, 32, 2800-6 | 6.1 | 28 |
| 485 | CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. *European Journal of Immunology*, **2002**, 32, 2084-92 | 6.1 | 105 |

| | | | |
|---|---|---|---|
| 484 | CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. *European Journal of Immunology*, **2002**, 32, 2356-64 | 6.1 | 146 |
| 483 | CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. *European Journal of Immunology*, **2002**, 32, 2617-22 | 6.1 | 75 |
| 482 | Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. *European Journal of Immunology*, **2002**, 32, 3235-45 | 6.1 | 100 |
| 481 | Dendritic Cells and Cancer: Prospects for Cancer Vaccination. **2002**, 177-203 | | |
| 480 | Stimulation of B lymphocytes, macrophages, and dendritic cells by protozoan DNA. **2002**, 4, 969-74 | | 18 |
| 479 | Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. **2002**, 106, 102-12 | | 101 |
| 478 | Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-gamma-independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA. **2002**, 119, 621-8 | | 10 |
| 477 | CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7). **2002**, 128, 467-73 | | 36 |
| 476 | Treatment of an immortalized APC cell line with both cytokines and LPS ensures effective T-cell activation in vitro. **2002**, 56, 492-503 | | 22 |
| 475 | Immature, but not inactive: the tolerogenic function of immature dendritic cells. **2002**, 80, 477-83 | | 283 |
| 474 | The role of tissue macrophages in the induction of proinflammatory cytokine production following intravenous injection of lipoplexes. **2002**, 9, 1120-6 | | 64 |
| 473 | Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. **2002**, 112, 1819-26 | | 41 |
| 472 | Mouse and human dendritic cell subtypes. **2002**, 2, 151-61 | | 1826 |
| 471 | CpG DNA: recognition by and activation of monocytes. **2002**, 4, 897-901 | | 62 |
| 470 | Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. **2002**, 81, 165-9 | | 102 |
| 469 | Differentiation of immunostimulatory stem-cell- and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion. **2002**, 20, 380-93 | | 14 |
| 468 | Recent advances in vaccine adjuvants. **2002**, 19, 715-28 | | 185 |
| 467 | Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. **2003**, 1002, 112-23 | | 32 |

| | | | |
|---|---|---|---|
| 466 | Apoptosis: programmed cell death at a molecular level. **2003**, 32, 345-69 | | 261 |
| 465 | Recent advances in veterinary vaccine adjuvants. **2003**, 33, 469-78 | | 130 |
| 464 | Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. **2003**, 30, 476-82 | | 23 |
| 463 | IL-4 regulates IL-12 p40 expression post-transcriptionally as well as via a promoter-based mechanism. *European Journal of Immunology*, **2003**, 33, 428-33 | 6.1 | 7 |
| 462 | Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides. *European Journal of Immunology*, **2003**, 33, 1382-92 | 6.1 | 38 |
| 461 | Bacterial DNA activates human neutrophils by a CpG-independent pathway. *European Journal of Immunology*, **2003**, 33, 3164-74 | 6.1 | 87 |
| 460 | Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. **2003**, 48, 642-50 | | 167 |
| 459 | Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. **2003**, 48, 1701-7 | | 56 |
| 458 | Dendritic cells in peripheral tolerance and immunity. **2003**, 111, 766-75 | | 38 |
| 457 | Murine dendritic cell development: difficulties associated with subset analysis. **2003**, 81, 239-46 | | 28 |
| 456 | Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin. **2003**, 110, 341-7 | | 35 |
| 455 | CpG oligodeoxynucleotides accelerate reovirus type 2-triggered insulitis in DBA/1 suckling mice. **2002**, 83, 217-23 | | 9 |
| 454 | Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor alpha, type I interferons, and interleukin-18. **2003**, 120, 990-7 | | 68 |
| 453 | CpG ODN enhances uptake of bacteria by mouse macrophages. **2003**, 132, 70-5 | | 42 |
| 452 | Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides. **2003**, 133, 227-32 | | 18 |
| 451 | Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. **2003**, 134, 217-24 | | 87 |
| 450 | CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. **2003**, 10, 1311-20 | | 49 |
| 449 | The imidazoquinolines and their place in the therapy of cutaneous disease. **2003**, 4, 1105-19 | | 21 |

| | | |
|---|---|---|
| 448 | Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. **2003**, 171, 3941-6 | 98 |
| 447 | CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum. **2003**, 21, 3307-18 | 39 |
| 446 | CpG-induced immunomodulation and intracellular bacterial killing in a chicken macrophage cell line. **2003**, 27, 823-34 | 80 |
| 445 | TOLL-like receptors linking innate and adaptive immune response. **2003**, 91, 1-12 | 300 |
| 444 | Adjuvant formulations and delivery systems for DNA vaccines. **2003**, 31, 243-54 | 69 |
| 443 | Molecular and cellular basis for designing gene vaccines against inflammatory autoimmune disease. **2003**, 9, 331-8 | 10 |
| 442 | Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. **2003**, 109, 64-71 | 69 |
| 441 | Immune regulation by regulatory T cells: implications for transplantation. **2003**, 11, 267-76 | 46 |
| 440 | Microparticles as vaccine adjuvants and delivery systems. **2003**, 2, 269-83 | 179 |
| 439 | Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling. **2003**, 278, 40590-600 | 47 |
| 438 | Activation of human dendritic cells is modulated by components of the outer membranes of Neisseria meningitidis. **2003**, 71, 5590-7 | 28 |
| 437 | Innate immunity in breast carcinoma. **2003**, 10, 301-8 | 7 |
| 436 | Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. **2003**, 198, 281-91 | 63 |
| 435 | Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. **2003**, 171, 1393-400 | 188 |
| 434 | Lipopolysaccharide-induced suppression of airway Th2 responses does not require IL-12 production by dendritic cells. **2003**, 171, 3645-54 | 88 |
| 433 | An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. **2003**, 171, 4920-6 | 68 |
| 432 | Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. **2003**, 71, 4398-404 | 21 |
| 431 | NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. **2003**, 170, 2540-8 | 104 |

| | | |
|---|---|---|
| 430 | Effective induction of acquired resistance to Listeria monocytogenes by immunizing mice with in vivo-infected dendritic cells. **2003**, 71, 117-25 | 18 |
| 429 | CpG DNA induces protective antiviral immune responses in Atlantic salmon (Salmo salar L.). **2003**, 77, 11471-9 | 108 |
| 428 | Influenza virus-induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. **2003**, 198, 133-44 | 151 |
| 427 | Toll-like receptor ligand links innate and adaptive immune responses by the production of heat-shock proteins. **2003**, 73, 574-83 | 25 |
| 426 | CpG DNA induces self and cross-hyporesponsiveness of RAW264.7 cells in response to CpG DNA and lipopolysaccharide: alterations in IL-1 receptor-associated kinase expression. **2003**, 170, 1052-61 | 104 |
| 425 | Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. **2003**, 170, 4483-8 | 177 |
| 424 | Stimulus-dependent deacylation of bacterial lipopolysaccharide by dendritic cells. **2003**, 197, 1745-54 | 37 |
| 423 | An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. **2003**, 84, 1623-1628 | 45 |
| 422 | Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. **2003**, 198, 267-79 | 601 |
| 421 | Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. **2003**, 170, 2802-5 | 89 |
| 420 | Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. **2003**, 13, 143-50 | 22 |
| 419 | Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. **2003**, 71, 857-63 | 120 |
| 418 | Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. **2003**, 71, 7014-22 | 48 |
| 417 | Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB x NZWF1 mice. **2003**, 12, 838-45 | 66 |
| 416 | A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. **2003**, 77, 953-62 | 134 |
| 415 | The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. **2003**, 102, 956-63 | 315 |
| 414 | Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. **2003**, 171, 5908-12 | 180 |
| 413 | Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner. **2003**, 170, 2367-73 | 31 |

| | | |
|---|---|---|
| 412 | Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. **2003**, 170, 1830-8 | 59 |
| 411 | In vivo impact of CpG1826 oligodeoxynucleotide on CD8 T cell primary responses and survival. **2003**, 171, 2995-3002 | 23 |
| 410 | Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38. **2003**, 278, 22563-73 | 48 |
| 409 | Salmonella enterica serovar Typhimurium expressing mutant lipid A with decreased endotoxicity causes maturation of murine dendritic cells. **2003**, 71, 6132-40 | 15 |
| 408 | Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages. **2003**, 278, 36334-40 | 49 |
| 407 | Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. **2003**, 171, 3697-704 | 66 |
| 406 | Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. **2003**, 197, 585-99 | 147 |
| 405 | Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. **2003**, 77, 3615-23 | 43 |
| 404 | Advances in vaccine adjuvants for infectious diseases. **2003**, 1, 309-20 | 32 |
| 403 | CpG motif in synthetic ODN primes respiratory burst of olive flounder Paralichthys olivaceus phagocytes and enhances protection against Edwardsiella tarda. **2003**, 56, 43-8 | 43 |
| 402 | Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. **2003**, 26, 313-9 | 32 |
| 401 | Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells. **2003**, 101, 305-10 | 263 |
| 400 | CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. **2003**, 8, e115-27 | 56 |
| 399 | Effects of CpG-oligodeoxynucleotides in Chronic Inflammation and Remodeling of Airway in a Murine Model of Bronchial Asthma. **2004**, 57, 543 | |
| 398 | Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. **2004**, 4, 697-709 | 30 |
| 397 | Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization. **2004**, 279, 17217-23 | 33 |
| 396 | Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. **2004**, 279, 15124-9 | 83 |
| 395 | Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. **2004**, 78, 1333-43 | 47 |

| | | | |
|---|---|---|---|
| 394 | Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. **2004**, 24, 901 | | 5 |
| 393 | Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. **2004**, 173, 6753-9 | | 144 |
| 392 | Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. **2004**, 172, 2137-46 | | 204 |
| 391 | CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. **2004**, 103, 2162-9 | | 79 |
| 390 | Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. **2004**, 9, 241-8 | | 75 |
| 389 | Tumor vaccines. **2004**, 82, 49-103 | | 21 |
| 388 | Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. **2004**, 72, 4494-502 | | 55 |
| 387 | Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. **2004**, 82, 617-27 | | 85 |
| 386 | CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. **2004**, 112, 117-25 | | 41 |
| 385 | Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells. **2004**, 123, 395-402 | | 23 |
| 384 | Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. **2004**, 123, 664-9 | | 22 |
| 383 | Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. **2004**, 199, 9-26 | | 578 |
| 382 | Use of CpG oligodeoxynucleotides as immune adjuvants. **2004**, 199, 201-16 | | 255 |
| 381 | Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFNbeta. **2004**, 149, 66-76 | | 21 |
| 380 | Development of immune assay system for both CpG and non-CpG DNA from lactic acid bacteria using a transfectant of swine Toll-like receptor 9. **2004**, 75, 377-382 | | 16 |
| 379 | Targeting split vaccines to the endosome improves vaccination. **2004**, 15, 538-42 | | 14 |
| 378 | CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model. **2004**, 122, 387-91 | | 16 |
| 377 | Treatment of neonatal mice with Flt3 ligand leads to changes in dendritic cell subpopulations associated with enhanced IL-12 and IFN-alpha production. *European Journal of Immunology*, **2004**, 34, 1849-60 | 6.1 | 28 |

| | | |
|---|---|---|
| 376 | HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells. **2004**, 93, 199-204 | 28 |
| 375 | Current developments of immunotherapy in the clinic. **2004**, 16, 130-6 | 65 |
| 374 | Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development. **2004**, 15, 467-74 | 88 |
| 373 | Customized antigens for desensitizing allergic patients. **2004**, 84, 79-129 | 13 |
| 372 | New Antiallergic Drugs. **2004**, 273-285 | |
| 371 | Protection of neonatal chicks against a lethal challenge of Escherichia coli using DNA containing cytosine-phosphodiester-guanine motifs. **2004**, 48, 813-22 | 63 |
| 370 | Mastitis increases mammary mRNA abundance of beta-defensin 5, toll-like-receptor 2 (TLR2), and TLR4 but not TLR9 in cattle. **2004**, 11, 174-85 | 195 |
| 369 | CD40/CD154 interactions at the interface of tolerance and immunity. **2004**, 22, 307-28 | 549 |
| 368 | Acid-degradable particles for protein-based vaccines: enhanced survival rate for tumor-challenged mice using ovalbumin model. **2004**, 15, 1281-8 | 78 |
| 367 | Efficacy of cellular vaccines and genetic adjuvants against bacterial kidney disease in chinook salmon (Oncorhynchus tshawytscha). **2004**, 16, 461-74 | 31 |
| 366 | Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. **2004**, 317, 992-9 | 86 |
| 365 | Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis. **2004**, 318, 60-6 | 5 |
| 364 | CpG oligodeoxynucleotides stimulate immune cell proliferation but not specific antibody production in rainbow trout (Oncorhynchus mykiss). **2004**, 101, 211-22 | 26 |
| 363 | CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. **2004**, 22, 2881-6 | 74 |
| 362 | CpG-DNA as immune response modifier. **2004**, 294, 345-54 | 25 |
| 361 | The immunobiology of the TLR9 subfamily. **2004**, 25, 381-6 | 283 |
| 360 | Bacterial DNA and RNA induce rat cardiac myocyte contraction depression in vitro. **2004**, 21, 364-9 | 17 |
| 359 | Discovery of novel immunostimulants by dendritic-cell-based functional screening. **2005**, 106, 3082-9 | 48 |

| | | |
|---|---|---|
| 358 | Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. **2005**, 106, 946-55 | 125 |
| 357 | Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. **2005**, 106, 3457-64 | 71 |
| 356 | Strong immunostimulation in murine immune cells by Lactobacillus rhamnosus GG DNA containing novel oligodeoxynucleotide pattern. **2005**, 7, 403-14 | 73 |
| 355 | Activation of murine dendritic cells and macrophages induced by Salmonella enterica serovar Typhimurium. **2005**, 115, 462-72 | 29 |
| 354 | CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells. **2005**, 140, 220-9 | 28 |
| 353 | Effects of CpG-ODN on gene expression in formation of foam cells. **2005**, 26, 1359-64 | |
| 352 | [Cancer immunotherapy with CpG-ODN]. **2005**, 21, 73-7 | 8 |
| 351 | CpG Oligodeoxynucleotides as a Future Vaccine for Allergic Diseases. **2005**, 54, 17-23 | 2 |
| 350 | Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. **2005**, 11, 2889-907 | 36 |
| 349 | Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. **2005**, 77, 898-905 | 56 |
| 348 | In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. **2005**, 54, 1428-36 | 50 |
| 347 | Pasteurella multocida toxin activates human monocyte-derived and murine bone marrow-derived dendritic cells in vitro but suppresses antibody production in vivo. **2005**, 73, 413-21 | 25 |
| 346 | Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. **2005**, 171, 1168-77 | 89 |
| 345 | B1-B cells are the main antigen presenting cells in CpG-ODN-stimulated peritoneal exudate cells. **2005**, 49, 89-95 | 8 |
| 344 | Effects of multiple copies of CpG on DNA vaccination. **2005**, 24, 292-8 | 16 |
| 343 | Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. **2005**, 11, 112-9 | 27 |
| 342 | Antigen-specific CD8+ T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway. **2005**, 12, 960-8 | 15 |
| 341 | Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. **2005**, 174, 7676-83 | 172 |

| | | |
|---|---|---|
| 340 | Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. **2005**, 174, 4373-80 | 87 |
| 339 | Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. **2005**, 174, 7815-22 | 54 |
| 338 | Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. **2005**, 175, 3569-76 | 66 |
| 337 | Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response. **2005**, 201, 1555-65 | 216 |
| 336 | CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on interleukin-17. **2005**, 191, 1368-76 | 36 |
| 335 | Dendritic cells activated with products released by schistosome larvae drive Th2-type immune responses, which can be inhibited by manipulation of CD40 costimulation. **2005**, 73, 395-402 | 68 |
| 334 | Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion. **2005**, 4, 218-24 | 24 |
| 333 | Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. **2005**, 78, 319-24 | 128 |
| 332 | DNA-based immunotherapy to treat atopic disease. **2005**, 95, 403-10; quiz 410-1, 451 | 10 |
| 331 | The role of adjuvants in the development of mucosal vaccines. **2005**, 5, 953-65 | 16 |
| 330 | Augmentation of T(H)-1 type response by immunoactive AT oligonucleotide from lactic acid bacteria via Toll-like receptor 9 signaling. **2005**, 326, 782-7 | 60 |
| 329 | Signal transduction of the prophenoloxidase activating system of prawn haemocytes triggered by CpG oligodeoxynucleotides. **2005**, 18, 149-62 | 30 |
| 328 | Porcine-specific CpG-oligodeoxynucleotide activates B-cells and increases the expression of MHC-II molecules on lymphocytes. **2005**, 105, 115-24 | 23 |
| 327 | Cloning of canine toll-like receptor 9 and its expression in dog tissues. **2005**, 106, 159-63 | 24 |
| 326 | Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression. **2005**, 108, 11-6 | 39 |
| 325 | Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120. **2005**, 23, 963-74 | 37 |
| 324 | TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). **2005**, 23, 5263-70 | 123 |
| 323 | Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. **2005**, 23, 5768-74 | 25 |

| | | |
|---|---|---|
| 322 | Current research on the immunostimulatory effects of CpG oligodeoxynucleotides in fish. **2005**, 246, 25-36 | 23 |
| 321 | Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. **2005**, 3, 45 | 37 |
| 320 | CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. **2005**, 129, 913-27 | 85 |
| 319 | Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. **2005**, 4, 315-27 | 11 |
| 318 | Tumor Immunology and Immunotherapy. **2006**, 254-268 | |
| 317 | Adjuvant activity of CpG oligodeoxynucleotides. **2006**, 25, 135-54 | 122 |
| 316 | Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. **2006**, 25, 183-213 | 62 |
| 315 | TLR9-independent activation of B lymphocytes by bacterial DNA. **2006**, 25, 253-61 | 16 |
| 314 | A newly identified CpG oligodeoxynucleotide motif that stimulates rainbow trout (Oncorhynchus mykiss) immune cells to produce immunomodulatory factors. **2006**, 30, 311-24 | 8 |
| 313 | Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guérin by Flt3-ligand generated dendritic cells. **2006**, 211, 557-65 | 62 |
| 312 | CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. **2006**, 6, 1586-96 | 31 |
| 311 | The in vitro effects of CpG oligodeoxynucleotides on the expression of cytokine genes in the common carp (Cyprinus carpio L.) head kidney cells. **2006**, 110, 79-85 | 21 |
| 310 | CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope. **2006**, 24, 1880-8 | 13 |
| 309 | An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. **2006**, 24, 2880-93 | 44 |
| 308 | Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. **2006**, 24, 5235-44 | 65 |
| 307 | Effects of DDA, CpG-ODN, and plasmid-encoded chicken IFN-gamma on protective immunity by a DNA vaccine against IBDV in chickens. **2006**, 7, 361-8 | 21 |
| 306 | Introduction to Some of the Issues and Mysteries Considered in this Book on Dendritic Cells. 3-11 | 1 |
| 305 | Cytokines Produced by Dendritic Cells. 355-383 | |

| | | | |
|---|---|---|---|
| 304 | Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. **2006**, 66, 1653-63 | | 17 |
| 303 | Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. **2006**, 61, 56-63 | | 32 |
| 302 | Elimination of CD4+ CD25+ regulatory T cells breaks down reovirus type 2-triggered and CpG ODN-induced prolonged mild autoimmune insulitis in DBA/1 mice. **2006**, 63, 116-24 | | 7 |
| 301 | Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. **2006**, 442, 651-6 | | 636 |
| 300 | Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. **2006**, 116, 331-5 | | 23 |
| 299 | Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. **2006**, 116, 407-12 | | 23 |
| 298 | Dendritic cells in germ-free and specific pathogen-free mice have similar phenotypes and in vitro antigen presenting function. **2006**, 102, 16-24 | | 33 |
| 297 | CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. **2006**, 1082, 137-50 | | 35 |
| 296 | Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. **2006**, 11, 113-22 | | 27 |
| 295 | CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. **2006**, 55, 515-27 | | 25 |
| 294 | Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. **2006**, 72, 42-8 | | 28 |
| 293 | Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. *European Journal of Immunology*, **2006**, 36, 12-20 | 6.1 | 143 |
| 292 | Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. *European Journal of Immunology*, **2006**, 36, 1951-62 | 6.1 | 19 |
| 291 | Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. *European Journal of Immunology*, **2006**, 36, 1764-71 | 6.1 | 99 |
| 290 | Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. *European Journal of Immunology*, **2006**, 36, 3248-55 | 6.1 | 102 |
| 289 | TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. *European Journal of Immunology*, **2006**, 36, 1684-93 | 6.1 | 155 |
| 288 | Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. *European Journal of Immunology*, **2006**, 36, 3238-47 | 6.1 | 40 |
| 287 | Towards a coronavirus-based HIV multigene vaccine. **2006**, 13, 353-60 | | 10 |

| | | |
|---|---|---|
| 286 | Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. **2006**, 87, 2253-2262 | 40 |
| 285 | Vaccine Adjuvants. **2006**, | 6 |
| 284 | Vector System: Plasmid DNA. **2006**, | |
| 283 | CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. **2006**, 5, 365-9 | 22 |
| 282 | Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. **2006**, 177, 6626-33 | 31 |
| 281 | Immunostimulatory PyNTTTTGT oligodeoxynucleotides: structural properties and refinement of the active motif. **2006**, 16, 275-85 | 11 |
| 280 | Development of Vaccine Adjuvants: A Historical Perspective. 1-31 | 6 |
| 279 | Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. **2007**, 39, 239-45 | 49 |
| 278 | Toll-like receptor 2-mediated dendritic cell activation by a Porphyromonas gingivalis synthetic lipopeptide. **2007**, 56, 459-465 | 17 |
| 277 | Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae-specific mucosal IgA responses in the middle ear. **2007**, 127, 809-15 | 6 |
| 276 | Protection of chickens against a lethal challenge of Escherichia coli by a vaccine containing CpG oligodeoxynucleotides as an adjuvant. **2007**, 51, 78-83 | 26 |
| 275 | Immune responses of mice to influenza subunit vaccine in combination with CIA07 as an adjuvant. **2007**, 51, 1099-107 | 6 |
| 274 | Bacterial DNA containing methylated CpG motifs retains immunostimulatory activity in synergy with modified lipopolysaccharides. **2007**, 51, 211-22 | 4 |
| 273 | Adjuvant effect of CpG-oligodeoxynucleotide in anti-fungal chemotherapy against fatal infection with Cryptococcus neoformans in mice. **2007**, 51, 741-6 | 8 |
| 272 | CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. **2007**, 81, 1075-85 | 31 |
| 271 | IFN-gamma negatively regulates CpG-induced IL-10 in bone marrow-derived dendritic cells. **2007**, 178, 211-8 | 24 |
| 270 | Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. **2007**, 178, 2979-86 | 193 |
| 269 | Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. **2007**, 14, 342-7 | 13 |

| | | | |
|---|---|---|---|
| 268 | Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. **2007**, 67, 11980-90 | | 40 |
| 267 | Mucosal Adjuvants and Delivery Systems. 295-326 | | 2 |
| 266 | Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody. **2007**, | | |
| 265 | Vaccination with porcine reproductive and respiratory syndrome killed virus vaccine and immunostimulatory oligodeoxynucleotides induces specific immunity in piglets. **2007**, 25, 1735-42 | | 15 |
| 264 | CpG oligodeoxynucleotides augment the immune responses of piglets to swine Pasteurella multocida living vaccine in vivo. **2007**, 83, 171-81 | | 12 |
| 263 | Vaccination with Newcastle disease vaccine and CpG oligodeoxynucleotides induces specific immunity and protection against Newcastle disease virus in SPF chicken. **2007**, 115, 216-22 | | 35 |
| 262 | Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. **2007**, 361, 537-42 | | 46 |
| 261 | Construction of a recombinant plasmid containing multi-copy CpG motifs and its effects on the innate immune responses of aquatic animals. **2007**, 23, 589-600 | | 20 |
| 260 | CpG oligodeoxynucleotides up-regulate antibacterial systems and induce protection against bacterial challenge in rainbow trout (Oncorhynchus mykiss). **2007**, 23, 781-92 | | 34 |
| 259 | Immunotherapy with CpG DNA conjugated with T-cell epitope peptide of an allergenic Cry j 2 protein is useful for control of allergic conditions in mice. **2007**, 7, 46-54 | | 21 |
| 258 | In vivo immunostimulatory effects of CpG ODN in newborn piglets. **2007**, 44, 1238-44 | | 11 |
| 257 | In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to swine streptococcic septicemia vaccine in weaned piglets. **2007**, 44, 1141-9 | | 15 |
| 256 | CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. **2007**, 44, 1095-104 | | 30 |
| 255 | Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. **2007**, 5, 19 | | 37 |
| 254 | Interferon: The 50th Anniversary. **2007**, | | 5 |
| 253 | . **2007**, | | 13 |
| 252 | Prevention of red cell alloimmunization by CD25 regulatory T cells in mouse models. **2007**, 82, 691-6 | | 63 |
| 251 | TLR9 activation is a key event for the maintenance of a mycobacterial antigen-elicited pulmonary granulomatous response. *European Journal of Immunology*, **2007**, 37, 2847-55 | 6.1 | 38 |

| | | |
|---|---|---|
| 250 | In vitro and in vivo evaluation of intrinsic immunogenicity of reporter and insulin gene therapy plasmids. **2007**, 9, 703-14 | 6 |
| 249 | Corticosterone impairs dendritic cell maturation and function. **2007**, 122, 279-90 | 64 |
| 248 | Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. **2007**, 150, 230-7 | 30 |
| 247 | Effects of LT-K63 and CpG2006 on phenotype and function of murine neonatal lymphoid cells. **2007** , 66, 426-34 | 13 |
| 246 | Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen. **2007**, 51, 496-504 | 8 |
| 245 | Flt3 ligand generates morphologically distinct semimature dendritic cells in ovalbumin-sensitized mice. **2007**, 83, 17-24 | 7 |
| 244 | Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. **2007**, 18, 77-83 | 57 |
| 243 | Transcription factors in the control of dendritic cell life cycle. **2007**, 37, 79-96 | 16 |
| 242 | Systemic administration of olygodeoxynucleotides with CpG motifs at priming phase reduces local Th2 response and late allergic rhinitis in BALB/c mice. **2008**, 31, 47-56 | 7 |
| 241 | The sweetness of the DNA backbone drives Toll-like receptor 9. **2008**, 20, 396-400 | 32 |
| 240 | Cryptococcus neoformans inhibits nitric oxide synthesis caused by CpG-oligodeoxynucleotide-stimulated macrophages in a fashion independent of capsular polysaccharides. **2008**, 52, 171-9 | 20 |
| 239 | Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. **2008**, 99, 1034-9 | 22 |
| 238 | Adjuvants LT-K63 and CpG enhance the activation of dendritic cells in neonatal mice. **2008**, 68, 469-75 | 9 |
| 237 | Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. **2008**, 9 Suppl 2, S5 | 28 |
| 236 | Treatment by CpG or Flt3-ligand does not affect mouse susceptibility to BSE prions. **2008**, 197, 74-80 | 4 |
| 235 | Toll-Like Receptors (TLRs) and Innate Immunity. **2008**, | 7 |
| 234 | Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by Panax notoginseng. **2008**, 116, 179-86 | 57 |
| 233 | TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. **2008**, 45, 244-52 | 49 |

| | | | |
|---|---|---|---|
| 232 | Effect of plasmid DNA encoding the porcine granulocyte-macrophage colony-stimulating factor on antigen-presenting cells in pigs. **2008**, 125, 354-60 | | 13 |
| 231 | CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. **2008**, 14, 973-984 | | 33 |
| 230 | Initiation of signal transduction of the respiratory burst of prawn haemocytes triggered by CpG oligodeoxynucleotides. **2008**, 24, 693-700 | | 12 |
| 229 | What happens to the DNA vaccine in fish? A review of current knowledge. **2008**, 25, 1-18 | | 113 |
| 228 | Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects. **2008**, 201-20 | | 12 |
| 227 | Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection. **2008**, 180, 6836-45 | | 71 |
| 226 | Systemic control of plasmacytoid dendritic cells by CD8+ T cells and commensal microbiota. **2008**, 180, 5843-52 | | 61 |
| 225 | Effect of CpG oligonucleotides on vaccine-induced B cell memory. **2008**, 181, 5785-90 | | 44 |
| 224 | CARD6 is interferon inducible but not involved in nucleotide-binding oligomerization domain protein signaling leading to NF-kappaB activation. **2008**, 28, 1541-52 | | 16 |
| 223 | Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. **2008**, 8, 230-42 | | 13 |
| 222 | Dendritic Cells. **2009**, 116-123 | | |
| 221 | 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. **2009**, 4, e6453 | | 115 |
| 220 | Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. *Clinical Cancer Research*, **2009**, 15, 7624-7633 | 12.9 | 20 |
| 219 | Luciferase therapeutic microcapsules for gene therapy. **2009**, 37, 235-44 | | 2 |
| 218 | Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice. **2009**, 2, 62-6 | | 2 |
| 217 | Strategies for optimizing targeting and delivery of mucosal HIV vaccines. *European Journal of Immunology*, **2009**, 39, 2657-69 | 6.1 | 21 |
| 216 | CpG-ODN enhances ingestion of apoptotic neutrophils by macrophages. **2009**, 9, 37-43 | | 6 |
| 215 | Strategies for enhancing DNA vaccine potency by targeting antigen-presenting cells. **2009**, 3, 478-485 | | 0 |

| | | |
|---|---|---|
| 214 | The immunogenicity of CpG-antigen conjugates. **2009**, 61, 243-7 | 39 |
| 213 | The in vitro and in ovo responses of chickens to TLR9 subfamily ligands. **2009**, 33, 660-7 | 29 |
| 212 | CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells. **2009**, 274, 160-4 | 14 |
| 211 | A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. **2009**, 27, 107-15 | 93 |
| 210 | A single-dose combination therapy that both prevents and treats anthrax infection. **2009**, 27, 1811-5 | 17 |
| 209 | The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. **2009**, 27, 2055-64 | 60 |
| 208 | Rescuing macrophage function following severe thermal injury. **2009**, 157, 158-60 | 1 |
| 207 | Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance?. **2009**, 70, 289-93 | 64 |
| 206 | CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. **2009**, 136, 278-87 | 37 |
| 205 | In vitro haematopoiesis of a novel dendritic-like cell present in murine spleen. **2010**, 5, 367-71 | 1 |
| 204 | Naked DNA Vaccines. **2010**, | |
| 203 | The utility of poly(Eglutamic acid) nanoparticles as antigen delivery carriers in dendritic cell-based cancer immunotherapy. **2010**, 33, 2003-7 | 14 |
| 202 | In vivo kinetics and biodistribution of a Hantaan virus DNA vaccine after intramuscular injection in mice. **2010**, 25, 177-82 | 3 |
| 201 | Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen. **2010**, 33, 1859-66 | 29 |
| 200 | Unmethylated CpG oligodeoxynucleotides activate head kidney leukocytes of Atlantic cod, Gadus morhua. **2010**, 36, 1151-8 | 5 |
| 199 | Glycogen synthase kinase 3-a master regulator of toll-like receptor-mediated chronic intestinal inflammation. **2010**, 16, 1850-8 | 49 |
| 198 | Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. **2010**, 17, 20-7 | 20 |
| 197 | Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses. **2010**, 88, 393-403 | 19 |

| | | |
|---|---|---|
| 196 | T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. **2010**, 59, 1347-54 | 18 |
| 195 | Gene Therapy with Plasmid DNA. **2010**, 457-499 | 3 |
| 194 | Mammalian telomeric DNA suppresses endotoxin-induced uveitis. **2010**, 285, 28806-11 | 4 |
| 193 | Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. **2010**, 2010, 986596 | 46 |
| 192 | Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung. **2010**, 2, 144-59 | 23 |
| 191 | Immunogenicity of protein therapeutics: The key causes, consequences and challenges. **2010**, 1, 314-322 | 225 |
| 190 | Short- and long-term changes in gene expression mediated by the activation of TLR9. **2010**, 47, 1317-24 | 35 |
| 189 | Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. **2010**, 300, 19-24 | 55 |
| 188 | CpG-induced secretion of MHCIIbeta and exosomes from salmon (Salmo salar) APCs. **2010**, 34, 29-41 | 47 |
| 187 | Murine J774 macrophages recognize LPS/IFN-g, non-CpG DNA or two-CpG DNA-containing sequences as immunologically distinct. **2010**, 22, 242-57 | 2 |
| 186 | Intrinsic nitric oxide-stimulatory activity of lipoteichoic acids from different Gram-positive bacteria. **2010**, 23, 300-10 | 9 |
| 185 | Identification and analysis of a CpG motif that protects turbot (Scophthalmus maximus) against bacterial challenge and enhances vaccine-induced specific immunity. **2010**, 28, 4153-61 | 47 |
| 184 | Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. **2010**, 70, 7788-99 | 201 |
| 183 | Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines. **2010**, 5, 1617-40 | 11 |
| 182 | Translational development of vaccination strategies in follicular NHL. **2011**, 24, 295-304 | 6 |
| 181 | An in silico DNA vaccine against Listeria monocytogenes. **2011**, 29, 6948-58 | 29 |
| 180 | Remembering Frank Fenner. **2011**, 89, 497-498 | 1 |
| 179 | Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs. **2011**, 48, 1494-504 | 7 |

| | | | |
|---|---|---|---|
| 178 | Progress towards a needle-free hepatitis B vaccine. **2011**, 28, 986-1012 | | 16 |
| 177 | Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals. **2011**, 68, 3505-18 | | 50 |
| 176 | New vistas on TLR9 activation. *European Journal of Immunology*, **2011**, 41, 2814-6 | 6.1 | 6 |
| 175 | Induction of pro-inflammatory mediators in Plasmodium berghei infected BALB/c mice breaks blood-brain-barrier and leads to cerebral malaria in an IL-12 dependent manner. **2011**, 13, 828-36 | | 21 |
| 174 | Chromosomal aberrations in chronic lymphocytic leukemia detected by conventional cytogenetics with DSP30 as a single agent: comparison with FISH. **2011**, 35, 1032-8 | | 14 |
| 173 | B cells do not take up bacterial DNA: an essential role for antigen in exposure of DNA to toll-like receptor-9. **2011**, 89, 517-25 | | 12 |
| 172 | Mucosal adjuvanticity of fibronectin-binding peptide (FBP) fused with Echinococcus multilocularis tetraspanin 3: systemic and local antibody responses. **2012**, 6, e1842 | | 4 |
| 171 | Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells. **2012**, 2, 102 | | 80 |
| 170 | Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. **2012**, 188, 3116-26 | | 95 |
| 169 | T granules in human platelets function in TLR9 organization and signaling. **2012**, 198, 561-74 | | 134 |
| 168 | Immunogenicity to biologics: mechanisms, prediction and reduction. **2012**, 60, 331-44 | | 76 |
| 167 | Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. **2012**, 746, 95-108 | | 15 |
| 166 | Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families. **2012**, 43, 60 | | 6 |
| 165 | Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer. **2012**, 14, 252-60 | | 15 |
| 164 | Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3. **2012**, 14, 665-73 | | 4 |
| 163 | Glioma. **2012**, | | 2 |
| 162 | CXCL10 is critical for the generation of protective CD8 T cell response induced by antigen pulsed CpG-ODN activated dendritic cells. **2012**, 7, e48727 | | 33 |
| 161 | Strategies to alleviate original antigenic sin responses to influenza viruses. **2012**, 109, 13751-6 | | 60 |

| | | | |
|---|---|---|---|
| 160 | Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. **2013**, | | 1 |
| 159 | Evaluation of the protective immune response induced in mice by immunization with Schistosoma mansoni schistosomula tegument (Smteg) in association with CpG-ODN. **2013**, 15, 28-36 | | 11 |
| 158 | Expression of IFN-γ induced by CpG-DNA stimulation in a human myeloid leukemia cell line KG-1. **2013**, 56, 553-558 | | 3 |
| 157 | CD4 blockade directly inhibits mouse and human CD4(+) T cell functions independent of Foxp3(+) Tregs. **2013**, 47, 73-82 | | 13 |
| 156 | Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. **2013**, 330, 190-9 | | 25 |
| 155 | Impact of microbes on autoimmune diseases. **2013**, 61, 175-86 | | 9 |
| 154 | Enhancement of the Immunity of Piglets to Pseudorabies Vaccine with Plasmids Containing Interleukin-6 Gene and CpG Motifs Encapsulated in Chitosan Nanoparticles. **2013**, 7, 8-14 | | 1 |
| 153 | What Have Dendritic Cells Ever Done for Adjuvant Design? Cellular and Molecular Methods for the Rational Development of Vaccine Adjuvants. **2013**, 131-154 | | |
| 152 | Gene Expression and Microarray Investigation of Dendrobium Mixture as Progressive Therapy for the Treatment of Type 2 Diabetes Mellitus. **2013**, 12, | | 2 |
| 151 | The linkage of innate and adaptive immune response during granulomatous development. **2013**, 4, 10 | | 31 |
| 150 | CpG and interleukin-15 synergize to enhance IFN-γ production by activated CD8+ T cells. **2013**, 2013, 924023 | | 4 |
| 149 | Studies on transcription initiated by cauliflower mosaic virus 35S promoter from transgenic crops using fish cell lines (HINAE, YO-K, RTG-2) and rainbow trout Oncorhynchus mykiss. **2013**, 19, 122-134 | | 3 |
| 148 | Mucosal immunization: a review of strategies and challenges. **2014**, 31, 273-303 | | 16 |
| 147 | Dendritic cell-secreted lipocalin2 induces CD8+ T-cell apoptosis, contributes to T-cell priming and leads to a TH1 phenotype. **2014**, 9, e101881 | | 21 |
| 146 | Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant. **2014**, 10, 3711-21 | | 9 |
| 145 | MyD88 signalling in myeloid cells is sufficient to prevent chronic mycobacterial infection. *European Journal of Immunology*, **2014**, 44, 1399-409 | 6.1 | 19 |
| 144 | Incorporation of CpG into a liposomal vaccine formulation increases the maturation of antigen-loaded dendritic cells and monocytes to improve local and systemic immunity. **2014**, 192, 3666-75 | | 20 |
| 143 | Diminazene aceturate (Berenil) modulates LPS induced pro-inflammatory cytokine production by inhibiting phosphorylation of MAPKs and STAT proteins. **2014**, 20, 760-73 | | 27 |

| | | |
|---|---|---|
| 142 | The stimulatory effect of different CpG oligonucleotides on the maturation of chicken bone marrow-derived dendritic cells. **2014**, 93, 63-9 | 13 |
| 141 | Murine and Human Model Systems for the Study of Dendritic Cell Immunobiology. **2016**, 35, 85-115 | 6 |
| 140 | Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. **2014**, 124, 1497-511 | 51 |
| 139 | Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. **2014**, 124, 3081-91 | 107 |
| 138 | A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms. **2015**, 5, 12578 | 16 |
| 137 | Multivalent Polymer Nanocomplex Targeting Endosomal Receptor of Immune Cells for Enhanced Antitumor and Systemic Memory Response. **2015**, 127, 8257-8261 | 7 |
| 136 | Multivalent Polymer Nanocomplex Targeting Endosomal Receptor of Immune Cells for Enhanced Antitumor and Systemic Memory Response. **2015**, 54, 8139-43 | 46 |
| 135 | Identification of Toxoplasma gondii protein fractions induce immune response against melanoma in mice. **2015**, 123, 800-9 | 2 |
| 134 | . **2015**, | 12 |
| 133 | Insights on Peptide Vaccines in Cancer Immunotherapy. **2015**, 1-27 | 2 |
| 132 | Cross talk between Leishmania donovani CpG DNA and Toll-like receptor 9: an immunoinformatics approach. **2015**, 459, 424-9 | 13 |
| 131 | Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703. **2015**, 25, 130-40 | 33 |
| 130 | Vaccination with Antigen Combined with ATP as a Vaccine Adjuvant Enhances Antigen-Specific Antibody Production via Dendritic Cell Activation. **2016**, 39, 1073-6 | 4 |
| 129 | Insight into the inhibition mechanism of kukoamine B against CpG DNA via binding and molecular docking analysis. **2016**, 6, 85756-85762 | 2 |
| 128 | Association between toll-like receptor polymorphisms and systemic lupus erythematosus: a meta-analysis update. **2016**, 25, 593-601 | 43 |
| 127 | Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides. **2016**, 105, 216-25 | 20 |
| 126 | Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide. **2017**, 266, 248-255 | 18 |
| 125 | Effect of Calcium Carbonate Encapsulation on the Activity of Orally Administered CpG Oligonucleotides. **2017**, 8, 243-249 | 6 |

| | | | |
|---|---|---|---|
| 124 | Microneedle-mediated delivery of viral vectored vaccines. **2017**, 14, 1177-1187 | | 3 |
| 123 | Intrapulmonary Delivery of CpG-ODN Microdroplets Provides Protection Against Escherichia coli Septicemia in Neonatal Broiler Chickens. **2017**, 61, 503-511 | | 10 |
| 122 | Microparticles and Nanoparticles for Cancer-Targeting Vaccines. **2017**, 171-183 | | 1 |
| 121 | Characterization of respiratory dendritic cells from equine lung tissues. **2017**, 13, 313 | | 4 |
| 120 | Synergistic oligodeoxynucleotide strongly promotes CpG-induced interleukin-6 production. **2017**, 18, 44 | | 10 |
| 119 | Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. **2018**, 13, 335-357 | | 16 |
| 118 | Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. **2018**, 11, | | 35 |
| 117 | Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase. **2018**, 171, 198-206 | | 63 |
| 116 | Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine. **2018**, 22, 558-567 | | 15 |
| 115 | Extending antigen release from particulate vaccines results in enhanced antitumor immune response. **2018**, 269, 393-404 | | 17 |
| 114 | A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. **2018**, 7, e1398876 | | 28 |
| 113 | Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity. **2018**, 16, 5123-5129 | | 1 |
| 112 | CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity. **2018**, 19, | | 17 |
| 111 | The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells. **2019**, 37, 4963-4974 | | 16 |
| 110 | Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators. **2019**, 6, 140 | | 10 |
| 109 | CpG enhances the immunogenicity of heterologous DNA-prime/protein-boost vaccination with the heavy chain myosin of Brugia malayi in BALB/c mice. **2019**, 118, 1943-1952 | | 4 |
| 108 | A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. *Cancers*, **2019**, 11, | 6.6 | 30 |
| 107 | Nucleic Acid-Based Functional Nanomaterials as Advanced Cancer Therapeutics. **2019**, 15, e1900172 | | 43 |

| | | |
|---|---|---|
| 106 | Triggers of Autoimmunity: The Role of Bacterial Infections in the Extracellular Exposure of Lupus Nuclear Autoantigens. **2019**, 10, 2608 | 43 |
| 105 | Metal-Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis. **2020**, 20, 829-840 | 34 |
| 104 | Oral priming with oligodeoxynucleotide particles from Lactobacillus rhamnosus GG attenuates symptoms of dextran sodium sulfate-induced acute colitis in mice. **2020**, 91, e13468 | 3 |
| 103 | Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. **2020**, 108, 27-37 | 6 |
| 102 | CpG-ODN Induces a Dose-Dependent Enrichment of Immunological Niches in the Spleen and Lungs of Neonatal Chicks That Correlates with the Protective Immunity against. **2020**, 2020, 2704728 | 2 |
| 101 | Self-Assembled DNA Nanostructures-Based Nanocarriers Enabled Functional Nucleic Acids Delivery.. **2020**, 3, 2779-2795 | 10 |
| 100 | Novel Toll-Like Receptor 9 Agonist Derived from Cryptococcus neoformans Attenuates Allergic Inflammation Leading to Asthma Onset in Mice. **2020**, 181, 651-664 | 2 |
| 99 | A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide. **2020**, 83, 106397 | 3 |
| 98 | Emerging role of microbiota in immunomodulation and cancer immunotherapy. **2021**, 70, 37-52 | 3 |
| 97 | Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. **2021**, 40, 108-125 | 24 |
| 96 | CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance. **2021**, 12, 590054 | 5 |
| 95 | The role of bacterial DNA containing CpG motifs in diseases. **2021**, 109, 991-998 | 1 |
| 94 | CpG Oligonucleotides as Vaccine Adjuvants. **2021**, 2197, 51-85 | 16 |
| 93 | Mechanism for Recognition of CpG DNA. **2006**, 69-86 | 2 |
| 92 | CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines. **2006**, 87-110 | 4 |
| 91 | Mechanisms of immune stimulation by bacterial DNA. **2001**, 21-33 | 1 |
| 90 | Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. **2001**, 77-84 | 1 |
| 89 | T cell activation and polarization by DC1 and DC2. **2000**, 251, 149-59 | 42 |

| | | |
|---|---|---|
| 88 | Bacterial CpG-DNA licenses TLR9. **2002**, 270, 145-54 | 47 |
| 87 | Mechanism of action of CpG DNA. **2000**, 247, 1-21 | 73 |
| 86 | CpG DNA in cancer immunotherapy. **2000**, 247, 157-70 | 15 |
| 85 | Immunostimulatory-sequence DNA is an effective mucosal adjuvant. **2000**, 247, 185-98 | 4 |
| 84 | Responses of human B cells to DNA and phosphorothioate oligodeoxynucleotides. **2000**, 247, 227-40 | 8 |
| 83 | Oligodeoxyribonucleotides with 5PACGT-3Por 5PTCGA-3Psequence induce production of interferons. **2000**, 247, 23-39 | 14 |
| 82 | Macrophage activation by immunostimulatory DNA. **2000**, 247, 41-58 | 43 |
| 81 | Consequences of bacterial CpG DNA-driven activation of antigen-presenting cells. **2000**, 247, 59-75 | 6 |
| 80 | Role of type I interferons in T cell activation induced by CpG DNA. **2000**, 247, 107-17 | 14 |
| 79 | Hematopoietic remodeling triggered by CpG DNA. **2000**, 247, 119-29 | 9 |
| 78 | CpG DNA augments the immunogenicity of plasmid DNA vaccines. **2000**, 247, 131-42 | 20 |
| 77 | Dendritic cell-based immunotherapy. **2003**, 276, 163-97 | 23 |
| 76 | Transcription factors in the control of dendritic cell life cycle. **2007**, 37, 79 | 1 |
| 75 | Dendritic cells as recipients of cytokine signals. **2001**, 187-202 | 2 |
| 74 | Dendritic cells and autoimmunity. **2001**, 459-cp1 | 1 |
| 73 | Molecular Biology of the Host-Microbe Interaction in Periodontal Diseases. **2012**, 285-293 | 3 |
| 72 | Interactions between Salmonella and dendritic cells: what happens along the way?. 279-298 | 1 |
| 71 | Costimulation via lymphocyte function-associated antigen 1 in the absence of CD28 ligation promotes anergy of naive CD4+ T cells. **2001**, 98, 241-6 | 24 |

| | | |
|---|---|---|
| 70 | Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. **1999**, 67, 3719-26 | 120 |
| 69 | Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach. **1999**, 73, 2280-7 | 13 |
| 68 | CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. **1999**, 73, 4120-6 | 98 |
| 67 | Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. **2003**, 112, 109-17 | 63 |
| 66 | Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. **2004**, 113, 990-7 | 136 |
| 65 | Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. **2003**, 112, 109-117 | 135 |
| 64 | TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. **2009**, 119, 33-46 | 93 |
| 63 | The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. **2000**, 68, 455-463 | 24 |
| 62 | CpG-containing oligodeoxynucleotides induce TNF-and IL-6 production but not degranulation from murine bone marrow-derived mast cells. **2001**, 69, 253-262 | 10 |
| 61 | CD8and CD8 subclasses of dendritic cells undergo phenotypic and functional maturation in vitro and in vivo. **2001**, 69, 951-958 | 19 |
| 60 | Muramyl dipeptide-Lys stimulates the function of human dendritic cells. **2001**, 70, 723-729 | 5 |
| 59 | Toll-like receptor 9 mediates CpG-DNA signaling. **2002**, 71, 538-544 | 44 |
| 58 | Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. **2002**, 71, 813-820 | 52 |
| 57 | CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice. **2002**, 72, 447-454 | 6 |
| 56 | CpG-DNA-induced IFN-production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors. **2002**, 72, 1011-1019 | 26 |
| 55 | Modulation of antibody responses against Gnathostoma spinigerum in mice immunized with crude antigen formulated in CpG oligonucleotide and montanide ISA720. **2013**, 51, 637-44 | 1 |
| 54 | CpG oligonucleotides as immune adjuvants. **2000**, 105-18 | 2 |
| 53 | CpG DNA co-stimulates antigen-reactive T cells. **2000**, 247, 93-105 | 1 |

52 The role of CpG in DNA vaccines. **2001**, 125-132

51 Systematic Modulation of Immune Responses by CpG DNA. **2001**, 201-218

50 Introduction to immunostimulatory DNA sequences. **2001**, 1-9

49 The response of human B lymphocytes to oligodeoxynucleotides. **2001**, 63-75

48 The role of immunostimulatory CpG-DNA in septic shock. **2001**, 167-171

47 Mucosal adjuvanticity of immunostimulatory DNA sequences. **2001**, 133-146

46 Pre-priming: a novel approach to DNA-based vaccination and immunomodulation. **2001**, 85-96

45 Immunostimulatory DNA sequences help to eradicate intracellular pathogens. **2001**, 147-152

44 Immunostimulatory DNA sequences and cancer therapy. **2001**, 107-116

43 Rescue of B cells from apoptosis by immune stimulatory CpG DNA. **2001**, 55-61

42 Activation of skin dendritic cells by immunostimulatory DNA. **2001**, 45-54

41 Introduction to Dendritic Cells. **2002**, 167-177

40 Development and Inhibition of Th2 Responses. **2002**, 247-291

39 Induction of B Cells by DNA Vaccines. **2003**, 66-81

38 Plasmid DNA-Mediated Gene Therapy. **2003**, 641-667 1

37 Dendritic Cells: Important Adjuvants During DNA Vaccination. **2003**, 39-59 1

36 Sustaining Transgene Expression in Vivo. **2003**,

35 Effects of CpG Oligodeoxynucleotides on Immune Responses and Expression of Cytokine Genes in Cultured Olive Flounder Paralichthys olivaceus. **2007**, 10, 1-7

| | | | |
|---|---|---|---|
| 34 | Natural DNA Recognition by Toll-Like Receptor 9 Does Not Rely upon CpG Motifs. **2008**, 77-83 | | |
| 33 | Use of CpG ODNs in Aquaculture. **2009**, 131-144 | | |
| 32 | Optimized Systemic Dosing with CpG DNA Enhances Dendritic Cell-Mediated Rejection of a Poorly Immunogenic Mammary Tumor in BALB/c Mice. **2009**, | | |
| 31 | Immune Adjuvants. **2009**, 627-652 | | |
| 30 | Transplantation Immunobiology. **2009**, 1835-1866 | | 1 |
| 29 | Modulation and Regulation of Gene Expression by CpG Oligonucleotides. **2010**, 191-208 | | |
| 28 | The effects of lactic acid bacteria-fermented soymilk extract on patients with colonic polyps: a randomized, double-blind, placebo-controlled pilot trial. **2014**, 25, 20-25 | | 1 |
| 27 | Immune Pathways Used in Nucleic Acid Vaccination. **1999**, 379-408 | | 0 |
| 26 | Toll-Like Receptors: Novel Molecular Targets for Antiviral Immunotherapy. 333-346 | | |
| 25 | Immunology of Pediatric Renal Transplantation. **2015**, 1-51 | | |
| 24 | Intradermal Vaccination. 71-95 | | |
| 23 | Immunology of Pediatric Renal Transplantation. **2016**, 2457-2500 | | |
| 22 | IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT. **2018**, 5, 16-23 | | |
| 21 | The role of immunostimulatory nucleic acids in septic shock. **2012**, 5, 1-23 | | 9 |
| 20 | [Chromosomal aberrations detection in chronic lymphocytic leukemia by conventional cytogenetics using DSP30 and IL-2]. *Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi*, **2020**, 41, 143-148 | 0.4 | 0 |
| 19 | Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus.. *Frontiers in Medicine*, **2022**, 9, 849120 | 4.9 | 2 |
| 18 | Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment.. *Cancers*, **2021**, 14, | 6.6 | 2 |
| 17 | Bioinorganic Chemistry of Zinc in relation to the Immune system. *ChemBioChem*, **2021**, | 3.8 | 0 |

| | | | |
|---|---|---|---|
| 16 | Activation of Dendritic Cells and Induction of T Cell Responses by Hpv 16 L1/E7 Chimeric Virus-Like Particles are Enhanced by Cpg ODN or Sorbitol. *Antiviral Therapy*, **2004**, 9, 479-489 | 1.6 | 13 |
| 15 | Potentiation of a Dendritic Cell Vaccine for Murine Renal Cell Carcinoma by CpG Oligonucleotides. *Clinical Cancer Research*, **2005**, 11, 1302-1311 | 12.9 | 3 |
| 14 | Multi-step screening of DNA/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression. *Nature Communications*, **2022**, 13, | 17.4 | 1 |
| 13 | TLR9 signaling activation via direct ligation and its functional consequences in CD4 +T cells. | | |
| 12 | Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. **2002**, 72, 1154-1163 | | 8 |
| 11 | Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. 12, | | 0 |
| 10 | Antibiotic-Free Nanoplasmids as Promising Alternatives for Conventional DNA Vectors. **2022**, 10, 1710 | | 0 |
| 9 | Lung dendritic cells and host immunity to infection. **2001**, 18, 692-704 | | 24 |
| 8 | CpG Oligodeoxynucleotides Can Circumvent the Th2 Polarization of Neonatal Responses to Vaccines But May Fail to Fully Redirect Th2 Responses Established by Neonatal Priming. **1999**, 162, 1611-1617 | | 39 |
| 7 | Immunostimulatory CpG-Oligodeoxynucleotides Cause Extramedullary Murine Hemopoiesis. **1999**, 162, 2368-2374 | | 15 |
| 6 | CpG Oligodeoxynucleotides Down-Regulate Macrophage Class II MHC Antigen Processing. **1999**, 163, 1188-1194 | | 18 |
| 5 | Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) Induces Stable Maturation of Functionally Active Human Dendritic Cells. **1999**, 163, 57-61 | | 27 |
| 4 | Priming MHC-I-Restricted Cytotoxic T Lymphocyte Responses to Exogenous Hepatitis B Surface Antigen Is CD4+ T Cell Dependent. **1999**, 163, 1880-1887 | | 12 |
| 3 | Cutting Edge: Bacterial DNA and LPS Act in Synergy in Inducing Nitric Oxide Production in RAW 264.7 Macrophages. **1999**, 163, 4095-4099 | | 12 |
| 2 | Bacterial/CpG DNA Down-Modulates Colony Stimulating Factor-1 Receptor Surface Expression on Murine Bone Marrow-Derived Macrophages with Concomitant Growth Arrest and Factor-Independent Survival. **1999**, 163, 6541-6550 | | 18 |
| 1 | DNA/DMXAA/Metal-Organic Framework Activator of Innate Immunity for Boosting Anticancer Immunity. 2210440 | | 0 |